Geneseeq

What Geneseeq does

Established in 2008, Geneseeq is an industry leader in Next-Generation Sequencing (NGS) fully committed to the research and clinical translation of NGS Genetic Sequencing in the field of personalized medicine. Geneseeq’s world-leading laboratories have successfully passed China’s National Center of Clinical Laboratories(NCCL) External Quality Assessment(EQA), College of American Pathologists(CAP) PT, European Molecular Genetics Quality Network(EMQN) PT, and received 3rd party medical laboratory and clinical PCR amplification laboratory qualifications.

Name

Geneseeq

Legal name

Geneseeq Technology Inc.

Website

https://na.geneseeq.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Geneseeq uses NGS technologies to help physicians make meaningful decisions for cancer treatment.

Ownership category

akta.pro rank

Product category

Precision Oncology Diagnostics

NAICS

Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Genomic Profiling & Sequencing-Based Precision Medicine (HLAAANAA)

akta.pro secondary industries

Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

Keywords

• NGS cancer diagnostics
• Precision oncology testing
• Companion diagnostic kits
• Liquid biopsy assays
• Minimal residual disease monitoring

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. IVD Kit Sales: Sale of FDA 510(k)-cleared, CE-IVD-marked, and NMPA-approved NGS IVD kits (GENESEEQPRIME®, PanTRKare™, Essencare™, liquid biopsy kits) to oncology laboratories and hospitals for decentralized clinical testing.
2. Central Laboratory Testing Services: NGS-based genomic testing services offered through the company's CAP/CLIA-accredited central laboratory. Includes pan-cancer genetic testing, ctDNA liquid biopsy, and MRD monitoring for external clients including hospitals and biopharma companies.
3. Research Services: Genomic research services provided to biopharma companies and academic institutions, including DNA/RNA sequencing, project design, QC/QA, and data analysis. Geneseeq has 2000+ research projects with biopharma and research partners.
4. Companion Diagnostic (CDx) Development Partnerships: Co-development of CDx kits with pharmaceutical partners (e.g., Roche, HUTCHMED/AstraZeneca, Jiangsu Vcare PharmaTech) for patient selection in clinical trials and drug approvals. Revenue through development fees, milestone payments, and future kit sales.
5. RUO Kit Solutions: Sale of Research Use Only (RUO) NGS kits to research institutions and biopharma for preclinical and translational research applications.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels5 records

Core offering

Geneseeq develops and commercializes next-generation sequencing (NGS)-based genomic profiling products and services for precision oncology. Its offerings include FDA 510(k)-cleared, CE-IVD-marked, and NMPA-approved IVD kits (e.g., GENESEEQPRIME 425-gene assay, PanTRKare NTRK fusion CDx), CAP/CLIA-accredited central laboratory testing services, MRD monitoring (SHIELDING), multi-cancer early detection (CanScan), hematologic malignancy panels (Hemasalus), and contract research services for biopharma and academic institutions.

Product overview

Geneseeq is a precision oncology company offering a comprehensive NGS-based genomic testing portfolio spanning products and services. The core offerings include GENESEEQPRIME (FDA 510(k)-cleared 425-gene tumor profiling assay), PanTRKare (China's first NGS-based pan-solid tumor CDx), CanScan (multi-cancer early detection with FDA Breakthrough Designation), SHIELDING (MRD monitoring), and Hemasalus (hematologic malignancies panels), all powered by the proprietary MERCURY multi-omics technology and GENESIS bioinformatics pipeline. Services include central lab testing, IVD kit solutions for decentralized deployment, and research services covering WGS, WES, RNA sequencing, and custom sequencing projects. The company operates CAP/CLIA-accredited facilities and holds regulatory approvals from FDA, CE-IVD, and NMPA.

Differentiator

Problem solved

Functional benefit

Brands

• GENESEEQPRIME: NGS Tumor Profiling Assay for detecting gene alterations across 425 cancer-related genes in solid malignant neoplasms. FDA 510(k) cleared, CE-IVD marked, NMPA approved.
• CanScan
• SHIELDING
• CALIBRATE
• PanTRKare
• Essencare
• MERCURY
• Hemasalus
• Pulmocan
• Radiotron
• PANCARNA
• GENESIS by GENESEEQ

Products and services

• Hemasalus Hematologic Malignancies Panel NGS gene panel for hematologic malignancy genomic profiling and MRD monitoring. Used in the SCENT-2 trial for ENKTL patients. Covers pan-cancer and cancer-type-specific applications for blood cancers.
• GENESEEQPRIME NGS Tumor Profiling Assay FDA 510(k)-cleared, CE-IVD-marked, and NMPA-approved in vitro diagnostic test using next-generation sequencing to detect tumor gene alterations across 425 cancer-related genes in patients with solid malignant neoplasms. Sold as a ready-to-use IVD kit to oncology laboratories for decentralized implementation.
• Pan-Cancer Gene Panels (Solid Tumors) Comprehensive pan-cancer NGS panels analyzing 400+ cancer-related genes across all solid tumor types and sample types, enabling comprehensive genomic profiling for treatment matching.
• Cancer Type-Specific Gene Panels (Solid Tumors) Targeted NGS gene panels designed for individual solid tumor cancer types, enabling focused and efficient genomic profiling for specific malignancies.
• CanScan Multi-Cancer Early Detection Blood-based multi-cancer early detection (MCED) solution utilizing low-depth whole-genome sequencing on circulating cell-free DNA. Achieves 99% specificity, predicts tissue of origin, and detects 13+ cancer types including those lacking effective standard-of-care screening (pancreatic, esophageal, gastric, endometrial, lymphoma).
• SHIELDING Minimal Residual Disease Monitoring MRD monitoring product for early and mid-stage solid tumors using ctDNA liquid biopsy for post-surgical recurrence monitoring. ShieldingUltra variant integrates mutation, copy number variation, and fragmentomics analysis. Demonstrated median 5-month lead time over radiographic imaging.
• PanTRKare NTRK Gene Fusion Detection Kit NMPA-approved NGS-based pan-solid tumor companion diagnostic test for detecting NTRK1/NTRK2/NTRK3 gene fusions. Validated across 7 hospitals, 33 tumor types, and 2,400+ clinical samples detecting 200+ unique NTRK fusion variants. Approved as CDx for Roche's ROZLYTREK (entrectinib).
• Essencare EGFR/ALK/ROS1/BRAF/KRAS/HER2 Mutation Detection Kit NMPA-approved NGS-based CDx kit using reversible terminator technology for detecting actionable mutations in EGFR, ALK, ROS1, BRAF, KRAS, and HER2 across solid tumors.
• EGFR/KRAS/MET Gene Mutation Detection Kit (Liquid Biopsy) NGS liquid biopsy kit that identifies mutations in multiple key tumor driver genes (EGFR, KRAS, MET) from circulating tumor DNA in a blood sample, eliminating the need for tumor tissue.
• Pulmocan Lung Cancer Panel Cancer type-specific 139-gene NGS panel for lung cancer genomic profiling used in MRD monitoring studies.
• PANCARNA Fusion Panel Targeted sequencing panel for comprehensive detection of cancer-related gene fusions across multiple cancer types.
• Radiotron Panel 474 cancer-related gene panel used in ctDNA MRD studies for chemoradiotherapy-treated inoperable NSCLC patients, with research published in Molecular Cancer.
• Central Lab Testing Service NGS-based clinical genomic testing services performed through CAP/CLIA/ISO15189-accredited central laboratories in Canada and China. Includes pan-cancer genetic testing, ctDNA liquid biopsy, MRD monitoring, and turnaround times of 5 business days for external hospitals and biopharma clients.
• Research Services Comprehensive genomic research services for biopharma and academic institutions including DNA sequencing (WGS, WES, targeted panel, methylation, customer-made library), RNA sequencing (whole transcriptome, small RNA, circular RNA), project design, QC/QA, and data analysis. Over 2,000 research projects delivered.

Quantifiable outcome

• CanScan® achieves 99% specificity and detects cancer tissue of origin with high accuracy, outperforming standard of care screening in prostate, lung, and liver cancers, and detecting cancer types without effective SOC screening such as esophageal, endometrial, gastric, pancreatic cancers and lymphoma.
• +8 more outcomes

Named customers7 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature12 records

Partnerships

Six partnerships are on record, tiered core.

• University Health Network (UHN) - Princess Margaret Cancer CentrecoreStrategic or Co-development Partner · 14 July 2026Geneseeq Canada named first commercial genomic testing partner in UHN's SHERLOCK study, a large prospective cancer genomics and molecular residual disease (MRD) research initiative. The collaboration supports genomic profiling and MRD monitoring for approximately 1,000 of the study's expected 7,000 participants over five years, spanning solid tumours and hematologic malignancies. This partnership reflects growing collaboration between academic institutions, healthcare systems, and genomic testing companies in advancing precision oncology research in Canada.
• RochecoreStrategic or Co-development Partner · 10 November 2025Geneseeq's PanTRKare™ NTRK1/NTRK2/NTRK3 Gene Fusion Detection Kit received NMPA marketing authorization as companion diagnostic for Roche's ROZLYTREK® (entrectinib), making it China's first NGS-based pan-solid tumor companion diagnostic test. The assay was validated through a multi-center clinical study involving seven hospitals, 33 tumor types, and more than 2,400 clinical samples that detected over 200 unique NTRK fusion variants. This regulatory milestone represents a strategic collaboration between Geneseeq and Roche in China's precision oncology market.
• Jiangsu Vcare PharmaTechcoreStrategic or Co-development Partner · 3 July 2024Partnership to develop a companion diagnostic (CDx) kit and advance the product launch of Vcare's pan-neurotrophic tyrosine receptor kinase (NTRK) inhibitor VC004 in China. VC004 is a highly selective next-generation NTRK inhibitor developed to overcome acquired resistance to first-generation NTRK inhibitors. Dr. Xiaonan Wang, Co-founder and CTO of Geneseeq, stated the aim to accelerate the development and clinical application of innovative drugs in China through this deep strategic collaboration.
• HUTCHMEDcoreStrategic or Co-development Partner · 24 June 2021Geneseeq served as the only designated NGS testing center in the NMPA approval process for savolitinib (developed by HUTCHMED and AstraZeneca) for NSCLC patients with MET exon 14 skipping alterations. Geneseeq, HUTCHMED, and AstraZeneca are collaborating on the potential development of a companion diagnostics kit for detecting MET mutations in lung cancer patients in China.
• AstraZenecacoreStrategic or Co-development Partner · 24 June 2021AstraZeneca partnered with Geneseeq and HUTCHMED in the MET inhibitor approval process for lung cancer patients in China. Geneseeq was the designated NGS testing center supporting the Phase II trial across 32 hospitals that led to the conditional approval of savolitinib by NMPA.
• IlluminacoreTechnology or Integration · 1 December 2018Collaboration between Geneseeq and Illumina to develop an oncogene detection kit for clinical diagnosis based on Illumina's sequencing technology. Both parties also conducted comprehensive cooperation in the promotion of high-throughput oncogene testing in China. At the time, Geneseeq's Multi-gene Detection Kit for Lung Cancer was entering CFDA's innovative approval green channel. This partnership leveraged Illumina's sequencing platforms and Geneseeq's assay development and regulatory expertise in China's NGS oncology market.

Scale indicators18 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Burning Rock Biotech: China-based NGS oncology company offering tumor profiling, liquid biopsy, and CDx services with multi-regional regulatory footprint. Most direct competitor in the China precision oncology market with overlapping CDx partnership model and NMPA-cleared panels.
• Guardant Health: US-based leader in liquid biopsy and genomic profiling for oncology, with FDA-approved Guardant360 CDx and active MRD/Early Detection programs. Compares to Geneseeq on NGS tumor profiling, liquid biopsy, and CDx strategy.
• Tempus AI: US precision medicine company combining NGS tumor profiling, liquid biopsy, MRD, and AI-driven analytics with biopharma partnerships. Strong overlap with Geneseeq's central lab services and biopharma data offerings.
• Caris Life Sciences: US-based molecular profiling and AI company offering MI Profile for solid tumors and a growing liquid biopsy / MRD portfolio. Comparable NGS-based profiling offering for oncologists and biopharma partners.
• Personalis: US-based NGS company focused on tumor profiling (NeXT Personal) and MRD (NeXT Personal Dx). Direct competitor in NGS-based liquid biopsy and CGP for solid tumors, with biopharma CDx services.
• Natera: US-based cell-free DNA testing company with Signatera MRD test as a flagship oncology product. Comparable in ctDNA-based MRD and tumor-informed testing strategy.

Broad incumbents

• Foundation Medicine: Roche subsidiary providing FoundationOne CDx and FoundationOne Liquid CDx for comprehensive genomic profiling. Serves as both a competitor and strategic benchmark for Geneseeq's CDx partnership with Roche for entrectinib.
• NeoGenomics: US clinical oncology lab offering comprehensive solid tumor and hematologic profiling, including NGS panels and liquid biopsy. Broader portfolio but overlapping oncology testing and pharma services.
• Exact Sciences: US-based cancer diagnostics leader with Cologuard and Oncotype products, plus emerging MRD (Oncodetect) and multi-cancer efforts. Comparable in MRD and early detection strategy, though much larger and broader.

Emerging players

• Admera Health: US-based NGS lab offering genomic profiling and liquid biopsy services for oncology. Niche / emerging player with overlapping CGP and biopharma research services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/GeneseeqInc
• LinkedInlinkedin.com/company/geneseeq-technology-inc

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Geneseeq